Immunomodulation of acellular dermal matrix through IL4 incorporation enhances vascularization and biointegration
WOUND REPAIR AND REGENERATION
Authors: Kang, Hannah; Nash, Victoria; Risser, Greg; Zhang, Meng; Salopek, Lisa; Fraser, Cassandra; Campbell, Christopher; Spiller, Kara; Cottler, Patrick S.
Abstract
Increased frequency of interleukin-4 and reduced frequency of interferon-gamma and IL-17-producing CD4+and CD8+cells in scleromyxedema
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Authors: Kalli, F.; Cioni, M.; Parodi, A.; Altosole, T.; Ferrera, F.; Barra, G.; De Palma, R.; Fenoglio, D.; Filaci, G.; Rongioletti, F.
Abstract
Background Little is known about the pathogenesis of scleromyxedema, a life-threatening fibromucinosis disease with immunological dysregulation. Objectives To investigate on T-cell phenotype, function and cytokine biology in search of new insights supporting the immunopathogenesis of the disease. Methods We analysed the frequency of circulating lymphocyte subsets, the T-cell maturation stage, the generation of antigen-specific T-cell lines and T-cell cytokine secretion. Results The analysis of T-cell maturation stage and the TCR spectratyping findings revealed that scleromyxedema patients showed clear immunological signs of long-lasting immune system activation and stimulation leading to a skewed T-cell repertoire. Moreover, these analyses showed that both CD4+ and CD8+ T cells from scleromyxedema patients have a profound deficiency (even after stimulation) relatively to the production of IFN-gamma and IL17 with respect to healthy donor control cells, while they are massively skewed towards IL4 secretion after stimulation. Conclusions Our data indicate that a chronic Th2-skewed T-cell response against an unknown target antigen leading to abnormally high IL4 secretion, a pro-fibrotic cytokine, is a main immunological hallmark of scleromyxedema patients. These results, never reported before, may have a translational therapeutic value due to the availability of anti-IL4 agents such as dupilumab.